

Annual Review of Physiology

Aging in the Cardiovascular System: Lessons from Hutchinson-Gilford Progeria Syndrome

Magda R. Hamczyk,^{1,2,*} Lara del Campo,^{1,2,*}
and Vicente Andrés^{1,2}

¹Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain; email: vandres@cnic.es

²CIBER de Enfermedades Cardiovasculares (CIBER-CV), 28029 Madrid, Spain

Annu. Rev. Physiol. 2018. 80:27–48

First published as a Review in Advance on September 20, 2017

The *Annual Review of Physiology* is online at physiol.annualreviews.org

<https://doi.org/10.1146/annurev-physiol-021317-121454>

Copyright © 2018 by Annual Reviews.
All rights reserved

*These authors contributed equally to this article.

Keywords

cardiovascular disease, atherosclerosis, vascular calcification, heart failure, prelamin A/lamin A, progerin

Abstract

Aging, the main risk factor for cardiovascular disease (CVD), is becoming progressively more prevalent in our societies. A better understanding of how aging promotes CVD is therefore urgently needed to develop new strategies to reduce disease burden. Atherosclerosis and heart failure contribute significantly to age-associated CVD-related morbimortality. CVD and aging are both accelerated in patients suffering from Hutchinson–Gilford progeria syndrome (HGPS), a rare genetic disorder caused by the prelamin A mutant progerin. Progerin causes extensive atherosclerosis and cardiac electrophysiological alterations that invariably lead to premature aging and death. This review summarizes the main structural and functional alterations to the cardiovascular system during physiological and premature aging and discusses the mechanisms underlying exaggerated CVD and aging induced by prelamin A and progerin. Because both proteins are expressed in normally aging non-HGPS individuals, and most hallmarks of normal aging occur in progeria, research on HGPS can identify mechanisms underlying physiological aging.



ANNUAL REVIEWS Further

Click here to view this article's online features:

- Download figures as PPT slides
- Navigate linked references
- Download citations
- Explore related articles
- Search keywords

1. LEARNING ABOUT PHYSIOLOGICAL CARDIOVASCULAR AGING FROM HUTCHINSON-GILFORD PROGERIA SYNDROME

CVD: cardiovascular disease

HGPS: Hutchinson-Gilford progeria syndrome

ZMPSTE24: zinc metallopeptidase STE24 (FACE-1)

Cardiovascular disease (CVD) is strongly associated with aging and is the leading cause of morbimortality worldwide (1, 2). The increasing prevalence of CVD is due in part to significant improvements in treatments, which have contributed to progressive societal aging by extending the life span. Population aging is already one of the most important demographic phenomena of our times in developed countries and is advancing rapidly in much of the developing world, bringing with it a major medical, social, and economic impact. For example, >20% of Europeans will be 65 or older by 2025, and by 2050, 19 countries are projected to have at least 10% of their population aged 80 years or over, with many having CVD and other age-associated disorders (3). The economic cost of treating CVD patients is significant and is projected to increase substantially in the coming years. For example, every day, EU member states collectively spend more than €4 billion on health care (4). Moreover, between 2010 and 2030, total direct medical costs of CVD in the United States are projected to triple, and a 61% increase in indirect costs is predicted due to CVD-related productivity loss (5). There is therefore an urgent need to define the mechanisms by which aging induces deterioration in the cardiovascular system independently of other risk factors, most of which are modifiable. This knowledge is essential for the provision of sustainable health care to a rapidly aging population.

Animal and human studies have identified four main causes of accumulated damage that are proposed to drive mammalian aging: genomic instability, telomere attrition, epigenetic alterations, and loss of proteostasis (6). These primary hallmarks of aging trigger deregulated nutrient sensing, mitochondrial dysfunction, and cellular senescence (antagonistic aging hallmarks), processes that lead to stem cell exhaustion and altered intercellular communication, which are the main culprits of aging (integrative hallmarks). These aging mechanisms have been identified through the comparison of young and normally aging animals or human subjects or through interventional studies assessing how alterations to specific genetic pathways and biochemical processes affect life span during physiological aging. However, there is evidence that research into Hutchinson-Gilford progeria syndrome (HGPS) (OMIM 176670) may shed light on the cellular and molecular mechanisms driving normal aging and associated CVD. HGPS patients exhibit premature aging associated with excessive atherosclerosis and the development of cardiac electrical defects, which lead to death typically in the early teens. The disease is caused by progerin, a variant of the precursor protein prelamin A produced because of a de novo mutation in the *LMNA* gene (7, 8) (see below). Other human progeroid syndromes have been linked to loss-of-function mutations in *ZMPSTE24* [zinc metallopeptidase STE24, also called FACE-1 (farnesylated protein-converting enzyme 1)], causing abnormal accumulation of prelamin A (9). Remarkably, all the hallmarks of normal aging proposed by López-Otín et al. (6) have been described in animal models of progeria, and some have also been reported in HGPS patients (reviewed in 10–12). Moreover, normal aging in non-HGPS individuals features low-level prelamin A and progerin expression in cells and tissues (reviewed in 10–13), including cells within the adventitia, media, and coronary atherosclerotic lesions (14). Oxidative stress and telomere shortening, both of which are thought to contribute to normal aging (6), have been reported to promote the expression of prelamin A (15) and progerin (16) in normal cells. In this review, we summarize the main structural and functional alterations in the cardiovascular system during physiological and premature aging and discuss cellular and molecular mechanisms implicated in the acceleration of CVD and aging induced by abnormal expression of prelamin A or progerin.

2. CARDIOVASCULAR DISEASE IN PHYSIOLOGICAL AGING

2.1. Cardiac Alterations

The following subsections summarize the main functional and structural alterations that occur in the heart during normal aging.

2.1.1. Heart failure. Heart failure (HF) is a complex clinical syndrome strongly associated with aging and results from any structural or functional impairment of ventricular filling or ejection that causes insufficient perfusion of peripheral tissues (17, 18). Clinical manifestations of HF are dyspnea and fatigue, limited capacity for exercise, and fluid retention, which may lead to pulmonary and/or peripheral edema. In a large proportion of aged patients, ejection fraction remains unaltered, indicating that overall systolic function is preserved (19, 20). Therefore, age-related HF in otherwise healthy individuals is attributed to a dysfunction in the diastolic filling of the left ventricle (LV), rather than an impairment of systolic function (21). Left ventricular dysfunction occurs when the LV loses its ability to relax normally, which is caused by stiffening of the cardiac muscle as a result of fibrosis (22).

Echocardiographically determined early (E) and late (A) ventricular velocities are both altered in aged patients. Aging is associated with a decline in early diastolic LV filling (23–25). Early diastolic filling occurs after closure of the aortic valve and depends mainly on the active relaxation of the myocardium, myocardial compliance, and the pressure gradient from the atrium to the ventricle (26). The delay in early emptying is compensated by a more vigorous end-diastolic atrial contraction, increasing the A wave and therefore reducing the E/A ratio (23–25). As a result, aging does not affect end-diastolic volume at rest. Mechanisms proposed for the reduced early diastolic LV filling rate during aging are fibrosis and stiffening of the ventricle (reduced compliance), as well as incomplete myofilament Ca^{2+} recruitment in the preceding systole (reducing active myocardial relaxation) (21, 27).

2.1.2. Left ventricular hypertrophy. The prevalence of left ventricular hypertrophy (LVH), defined as an increase in LV wall thickness, increases dramatically with age in men and women (28–30) and stands out as a powerful independent predictor for mortality and morbidity, especially in the elderly (28, 31). Age-associated LVH is the result of a progressive pathologic cardiac remodeling involving cardiomyocyte hypertrophy and death and collagen deposition (21, 32). Blood pressure, obesity, valve disease, and myocardial infarction are independent identified conditions that can induce the development of LVH (29).

2.1.3. Cardiac fibrosis. Aging is associated with increased collagen content in the extracellular matrix (ECM), leading to cardiac fibrosis and the development of LVH (33). However, the precise mechanisms underlying age-related cardiac remodeling remain largely undefined. Cardiac fibrosis during aging has been attributed to the downregulation of matrix-degrading pathways and increased collagen cross-linking, rather than to increased collagen synthesis, the main cause of cardiac fibrosis in hypertension (34). Fibrosis is also activated to replace dead cardiac tissue (34, 35). Fibrosis is a major predisposing factor for mechanical and electrical dysfunction in HF, as it reduces the ability of the myocardium to conduct electrical impulses, relax and stretch properly, and diffuse oxygen, thus increasing the age-related incidence of LV and heart valve dysfunction and arrhythmias (36). The fibrosis-induced increase in cardiomyocyte workload combines with the impairment of the physiological environment to promote additional cardiomyocyte cell death and the replacement of lost cells by fibrotic material, generating a vicious cycle that aggravates cardiac dysfunction (37). Furthermore, enhanced collagen deposition and cardiomyocyte

HF: heart failure
LV: left ventricle
LVH: left ventricular hypertrophy
ECM: extracellular matrix

hypertrophy are thought to be consequences of increased LV workload induced by vessel stiffening (34), highlighting the importance of vascular dysfunction in the development of age-associated CVD.

2.1.4. Cardiac valve disease. Mitral and aortic valves become thicker and stiffer with age, leading to valve dysfunction and regurgitation (36, 38). Age-related functional impairment of heart valves due to calcification and connective tissue degeneration might be caused by progressive alterations to the ECM, resulting in loss of elastomechanical force, weakness, and stiffening, which drive inflammation and further calcification (36, 38).

2.1.5. Heart rhythm alterations. Cardiac output at rest is not modified by aging, as both stroke volume and heart rate are maintained. However, the aged heart has reduced capacity to increase heart rate, and therefore cardiac output, in response to physical exercise. Hence, the maximum acute cardiac output reserve decreases by approximately 30% between the ages of 20 and 85 years (39). This effect may account for the age-associated reduced physical performance capacity and increased fatigue after exercise.

The prevalence of atrial fibrillation also increases with age and is epidemiologically associated with hypertension, heart valve disease, and HF (40). Factors suggested to contribute to atrial fibrillation are overt sinus node dysfunction and altered autonomous nervous regulation (41, 42). Aging reduces the intrinsic pacemaker activity of the sinoatrial node, likely due to fibrosis, alterations to electrical conduction, and changes in the sinoatrial node action potential (43).

2.1.6. Defective autonomic cardiovascular regulation. Alterations in the autonomic regulation of the heart and blood vessels during aging have a major impact on cardiac and vascular functions, such as heart rate, myocardial contractility, myocardial relaxation, and vascular regulation of blood flow. Aging-associated autonomic cardiovascular dysregulation includes elevated sympathetic activity linked to increased plasma levels of catecholamines, decreased β -adrenergic sensitivity, and decreased baroreflex sensitivity. The causes of these aging-related alterations remain poorly understood; however, increased sympathetic activity has been suggested as a mechanism to compensate the decreases in baroreflex sensitivity and β -adrenergic postsynaptic activity (21, 44–46).

2.2. Vascular Alterations

This section summarizes the main functional and structural alterations that aging causes in the vascular system.

2.2.1. Hypertension. The classic assumption that aging contributes to hypertension is disputed today (47). Data from longitudinal studies led some authors to propose that the aging-associated sympathetic hyperactivity increases blood pressure (44); however, whether this increase crosses the threshold to hypertension depends on the initial blood pressure values in youth (48). Sun (49) emphasizes the etiological involvement of vascular stiffening in blood pressure elevation, suggesting that large artery stiffening underlies the drop in baroreflex sensitivity, which is subsequently compensated by sympathetic activation. In humans, the baroreflexes rapidly and reflexively modulate blood pressure, and their impairment with aging is therefore also associated with an increase in blood pressure variability (50, 51).

2.2.2. Vascular stiffening. Two major age-related vascular alterations are arterial stiffening and endothelial dysfunction (1, 2, 52). Arterial stiffening is noninvasively calculated from the pulse

wave velocity (PWV) and is a highly reliable, blood pressure-independent predictor of cardiac events in a variety of adult populations, including the elderly (53). Carotid-femoral PWV increases progressively from approximately the age of 50, and arterial stiffness can reach an incidence of 64–74% in the geriatric population (54, 55). Increased stiffness of the large arteries places a strain on the heart, leading to cardiac fibrosis and HF. Vessel stiffening also sets the stage for the initiation and progression of hypertension and atherosclerosis in the elderly by promoting cellular dysfunction in the vessel wall (56). The mechanisms underlying age-induced arterial stiffening include ECM alterations and associated increases in fibrosis and inflammation (49). Age-induced alterations in ECM structure and composition in the artery wall are due to increased collagen deposition and cross-linking, accumulation of advanced glycation end products, and elastin fiber breakage. Progressive fibrosis in the tunica media is one of the suspected underlying mechanisms that predispose inflammation and atherosclerosis during aging (45, 56, 57).

PWV: pulse wave velocity

EC: endothelial cell

VSMC: vascular smooth muscle cell

2.2.3. Endothelial dysfunction. Aging is also associated with endothelial dysfunction, which alters homeostatic endothelial cell (EC) function, including the control of vascular tone, vascular permeability, and inflammation (52). Age-related accumulation of dysfunctional ECs is associated with decreased bioavailability of the cellular messenger nitric oxide (52), which increases permeability and inflammation and triggers a positive feedback loop that aggravates the phenomenon in the long term (58). Endothelial dysfunction is a major determinant of both the initiation and progression of atherosclerosis, a degenerative process that occurs within large elastic arteries during aging (2, 47, 59).

2.2.4. Atherosclerosis. Age-associated vascular wall remodeling includes luminal enlargement as well as intimal and medial thickening (60). An increased intima-to-media ratio is a harbinger of human atherosclerosis (47) and is an independent predictor of future cardiovascular events (61). Intimal thickening is initiated and sustained by the recruitment of blood-borne leukocytes, which is triggered by the activation of adhesion molecules on dysfunctional ECs (62). Neointimal leukocytes trigger a complex local immune response that further promotes leukocyte recruitment and induces the migration of vascular smooth muscle cells (VSMCs) from the tunica media to the growing atherosclerotic lesion. Activated neointimal VSMCs switch from a contractile to a synthetic phenotype characterized by dedifferentiation, proliferation, and abundant secretion of ECM components (63, 64).


There is persistent controversy about whether atherosclerosis results from the accumulation of risk factors with aging or, conversely, whether aging itself promotes atherosclerosis independently of other factors. The important influence of risk factor exposure is attested by the lack of atherosclerosis in elderly members of isolated tribal societies (65) and by its presence in children with a high risk exposure (66), suggesting that it is possible to age without atherosclerosis. However, signs of atherosclerosis have been detected in ancient mummified human remains from societies not exposed to modern risk factors (67). This, together with the incidence of atherosclerosis in individuals with HGPS and other premature aging syndromes, supports the idea that the predominant atherosclerosis risk factor is aging itself.

3. CARDIOVASCULAR DISEASE IN HUTCHINSON-GILFORD PROGERIA SYNDROME PATIENTS


HGPS is an ultrarare human genetic disease, with an estimated prevalence of 1 in 20 million people (<http://www.progeriaresearch.org>). The disease is characterized by accelerated aging caused by a de novo mutation in the *LMNA* gene (7, 8). In normal cells, alternative splicing

of *LMNA* transcripts gives rise to two major A-type lamin variants (lamin A and lamin C) as well as minor variants (lamin A Δ 10 and the germline-specific lamin C2) (68–70). The precursor protein prelamin A undergoes several posttranslational modifications to yield mature lamin A (**Figure 1a**). First, a farnesyltransferase farnesylates the cysteine residue at the C-terminal cysteine-serine-isoleucine-methionine (CSIM) motif. The three C-terminal amino acids are then

a Wild-type *LMNA* gene



b Classic HGPS mutation of *LMNA* gene



removed, enabling methylation of the new C-terminus by isoprenylcysteine carboxyl methyltransferase (ICMT). Finally, the zinc metalloprotease ZMPSTE24/FACE-1 removes the farnesylated and carboxymethylated 15 C-terminal residues. Mature lamin A is then incorporated into the nuclear lamina, which is a protein scaffolding network that underlies the inner nuclear membrane, providing mechanical strength to the nucleus and regulating many cellular functions, including DNA replication and repair, chromatin organization, signal transduction, and gene transcription (71).

Classic progeria in most HGPS patients is caused by a heterozygous de novo c.1824C>T (p.G608G) point mutation in the *LMNA* gene (7, 8). This synonymous mutation creates an aberrant splice site in exon 11 that deletes 150 nucleotides, resulting in the synthesis of a truncated prelamin A variant called progerin ($\Delta 50$ prelamin A) (Figure 1b). A lack of the 50 amino acids at the progerin C-terminus impedes cleavage of the terminal 15 amino acids, causing the accumulation of permanently farnesylated and carboxymethylated progerin. ZMPSTE24/FACE-1-inactivating mutations (including both homozygous and compound heterozygous mutations) provoke the accumulation of farnesylated prelamin A and are also linked to human progeroid syndromes (9). Abnormal prelamin A and progerin expression causes multiple structural and functional alterations that affect signal transduction, gene transcription, and chromatin organization, ultimately provoking growth arrest, cell senescence, cell death, and the acceleration of organismal aging (11, 71) (Figure 1b). Remarkably, most of the processes affected in HGPS are implicated in normal aging (6).

HGPS patients appear normal at birth but start to develop symptoms during the first 12–18 months of life. The disease is characterized by failure to thrive, abnormal dentition, alopecia, lipodystrophy, skin abnormalities, muscle weakness, joint contractures, osteoporosis, and osteolysis, the last four of which progressively impair walking and other motor activities. However, the most severe medical problem in HGPS patients is atherosclerosis and cardiac electrical abnormalities, causing premature death at an average age of 14.6 years, mainly from myocardial infarction or stroke (72–76).

Many of the cardiovascular alterations in HGPS patients also feature in physiological aging (Table 1). However, unlike the physiologically elderly, HGPS patients have an elevated platelet count and a prolonged prothrombin time (75) and typically lack or are only mildly affected by most traditional cardiovascular risk factors. For example, HGPS patients and healthy children have similar levels of mean plasma cholesterol, low-density lipoprotein (LDL)-bound and high-density lipoprotein (HDL)-bound cholesterol, triglyceride, and median C-reactive protein (74, 75, 77). Moreover, ~30% of HGPS patients show only a slight elevation of systolic and diastolic blood pressures compared with age-matched healthy children (74, 75, 78). The study of CVD in HGPS therefore offers a unique opportunity to identify mechanisms that cause age-associated

ICMT:
isoprenylcysteine
carboxyl
methyltransferase

Figure 1

Prelamin A processing in normal and HGPS cells. (a) In control cells carrying the wild-type *LMNA* sequence, normal splicing between exons 11 and 12 gives rise to prelamin A, which undergoes sequential posttranslational modifications to yield mature lamin A. Final cleavage by the protease ZMPSTE24 (also known as FACE-1) removes the farnesylated and carboxymethylated C-terminus. ZMPSTE24-inactivating mutations lead to accumulation of permanently farnesylated and carboxymethylated prelamin A, which accelerates aging. (b) Classic HGPS is caused by a heterozygous de novo synonymous mutation in the *LMNA* gene (c.1824C>T; p.G608G), which results in aberrant splicing between exons 11–12 and the synthesis of progerin. Lack of the 50 amino acid residues encompassing the ZMPSTE24 cleavage site prevents removal of the progerin C-terminus, which remains permanently farnesylated and carboxymethylated, causing multiple cellular alterations and premature aging and death. Abbreviations: CSIM, cysteine-serine-isoleucine-methionine; FACE-1, farnesylated protein-converting enzyme 1; FACE-2, farnesylated protein-converting enzyme 2; FTase, farnesyltransferase; HGPS, Hutchinson–Gilford progeria syndrome; ICMT, isoprenylcysteine carboxyl methyltransferase; RCE-1, Ras-converting CAAX endopeptidase 1 (FACE-2); ZMPSTE24, zinc metallopeptidase STE24 (FACE-1).

Table 1 Age-associated structural and functional changes in the cardiovascular system: physiological versus premature aging

Changes	Physiological aging	Premature aging
Heart failure	Yes	Yes
Left ventricular diastolic dysfunction	Yes	Yes
Ventricular hypertrophy	Yes	Yes
Cardiac fibrosis	Yes	Yes
Heart valve dysfunction	Yes	Yes
Increased sympathetic activity	Yes	Yes
Decreased baroreflex sensitivity	Yes	Yes
Intima-media thickening	Yes	Yes
Vascular stiffening	Yes	Yes
Vascular fibrosis	Yes	Yes
Endothelial dysfunction	Yes	No
Atherosclerosis	Yes	Yes
Vascular calcification	Yes	Yes
Hypertension	Yes	Yes
Elevated platelet count	No	Yes
Prolonged prothrombin time	No	Yes

cardiovascular damage in the absence of other risk factors or aging-associated chronic diseases that can secondarily influence cardiovascular health.

As with normal aging, noninvasive imaging in HGPS patients detects patent carotid plaques only at later stages (74, 75, 78). However, arterial stenosis affects HGPS patients of all ages and may be an early indicator of atherosclerotic plaque formation (74). In addition to alterations typically seen in normal aging, such as inflammation, VSMC loss, and plaque erosion and rupture, atherosclerotic vessels in HGPS patients also uniquely feature prominent adventitial thickening and fibrosis (14, 79). Another feature of physiological aging also found in HGPS is vascular calcification (VC), which is associated with augmented CVD-associated morbimortality in the general population (80); VC affects the aorta and aortic and mitral valves of some HGPS patients and can cause aortic and/or mitral regurgitation (14, 75, 81–84). Neuroimaging studies in a 25-patient cohort identified early and clinically silent stroke as a prevalent characteristic of HGPS (85). Stroke in HGPS patients can also leave neurologic sequelae (86).

HGPS is also characterized by vessel stiffening, an alteration associated with physiological aging that independently predicts the incidence of future cardiovascular events. Analysis of a 21-patient cohort identified vascular stiffening as an early and pervasive feature of the disease, detecting PWV values comparable to those typically seen in adults older than 60 years (74). Although carotid intima-media thickness is normal in HGPS patients, their carotid arteries have an above-normal echodensity, especially in the adventitia, consistent with elevated vascular fibrosis seen during autopsy (14, 74, 75, 87). An altered ankle-brachial index in HGPS indicates peripheral artery disease and vascular dysfunction (74, 82); nevertheless, endothelial vasodilator function seems to be preserved, as there is no alteration to flow-mediated dilation, which is a measure of endothelial vasodilator function (75). Further studies are warranted to identify the mechanisms underlying progerin-induced vascular dysfunction.

A subset of HGPS patients show electrocardiographic alterations, including repolarization abnormalities, such as ST depression/elevation and negative and biphasic T waves; these abnormalities are especially evident in patients with LV hypertrophy, diastolic dysfunction, or cardiac

VC: vascular calcification

Table 2 Mouse models of Hutchinson–Gilford progeria syndrome

Model	Gene or transgene	A-type lamin expression	Vascular alterations	Cardiac alterations	Premature aging	Reference(s)
<i>Lmna</i> ^{HG/+}	<i>Lmna</i>	Progerin, lamin A/C	No	NR	Yes	88, 89
<i>Lmna</i> ^{HG/HG}	<i>Lmna</i>	Progerin	NR	NR	Yes	88, 89
<i>BAC-G608G</i>	Tg(<i>LMNA</i> * G608G)	Lamin A/C, human progerin	Yes	No	No	90
<i>Lmna</i> ^{G609G/+}	<i>Lmna</i>	Progerin, lamin A/C	Yes	NR	Yes	92, 93
<i>Lmna</i> ^{G609G/G609G}	<i>Lmna</i>	Progerin, lamin C, residual lamin A	Yes	Yes	Yes	92
<i>Lmna</i> ^{G609G/G609G}	<i>Lmna</i>	Progerin, lamin C, residual lamin A	Yes	NR	Yes	94
<i>Zmpste24</i> ^{-/-}	<i>Zmpste24</i>	Prelamin A, lamin C	No	No	Yes	99
<i>Zmpste24</i> ^{-/-}	<i>Zmpste24</i>	Prelamin A, lamin C	No	Yes	Yes	76, 100

Abbreviation: NR, not reported.

valve dysfunction at advanced disease stages (74–76, 81, 84). Cardiac rhythm in HGPS patients is in the normal range; however, heart rate tends to be below normal in older patients (76).

In summary, the key features of CVD in HGPS patients are vascular stiffening and remodeling, with prominent medial and adventitial fibrosis, VSMC loss, accelerated atherosclerosis, and premature death from myocardial infarction or stroke. Premature death in HGPS might also be linked to arrhythmias resulting from cardiac electrical defects. Additional studies are needed to define the precise mechanisms through which progerin expression accelerates CVD and to elucidate the relative contribution of cardiac and vascular alterations to premature death in HGPS.

4. MOUSE MODELS OF PROGERIA

An estimated 350 to 400 children live with HGPS worldwide (<http://www.progeriaresearch.org>). This very low number presents many challenges, both for research to identify mechanisms underlying premature aging and associated CVD and for conducting clinical trials to assess new therapies. To facilitate HGPS research, a number of strategies have been used over the past 15 years to create mouse models of progeria (Table 2). Although none of these models fully recapitulates HGPS symptoms, probably due to interspecies differences, they have been extremely useful in identifying molecular and cellular mechanisms underlying progeria and in testing therapeutic strategies. This section summarizes the main characteristics of available progeroid mouse models.

4.1. *Lmna*^{HG}

Yang and colleagues (88, 89) produced the first HGPS-like mouse model, creating a knock-in mouse line carrying a mutant progerin-expressing allele referred to as *Lmna*^{HG} (Hutchinson–Gilford). Heterozygous *Lmna*^{HG/+} mice express progerin together with lamin A and C and start losing weight at 6–8 weeks of age; they either die or require euthanasia by 4–8 months of age (compared with a >2-year average life span in wild-type mice). Homozygous *Lmna*^{HG/HG} mice exclusively express progerin and have a more severe phenotype, dying by 3–4 weeks of age. Both *Lmna*^{HG/+} and *Lmna*^{HG/HG} present osteoporosis, loss of subcutaneous fat, and alopecia, which are features observed in HGPS patients. Nevertheless, these models show no signs of CVD (89).

4.2. *G608G BAC*

Varga et al. (90) generated *G608G BAC* transgenic mice using a bacterial artificial chromosome (BAC) that harbors a version of the human *LMNA* gene containing the HGPS-causing c.1824C>T

BAC: bacterial artificial chromosome

(p.G608G) mutation. These mice express human progerin and endogenous mouse lamin A/C but show no overt progeroid features (90). However, autopsy studies revealed progressive loss of VSMCs in the large arteries of *G608G BAC* mice starting at 5 months of age. This is accompanied by collagen and proteoglycan deposition in the media, broken elastic fibers, and thickened adventitia and medial layers (90), all of which are vascular pathologies described in human patients (14, 79, 91). Consistent with the aortic phenotype of *G608G BAC* mice, these animals show impaired vascular responsiveness after sodium nitroprusside administration; however, *G608G BAC* mice present no overt signs of atherosclerotic plaque formation (90).

4.3. *Lmna*^{G609G/G609G}

Osorio et al. (92) generated *Lmna*^{G609G} knock-in mice carrying a c.1827C>T (p.G609G) mutation in the endogenous mouse *Lmna* gene, equivalent to the HGPS-causing human mutation *LMNA* c.1824C>T (p.G608G). The *Lmna*^{G609G} allele gives rise to progerin (via aberrant splicing), lamin C, and some residual lamin A, mimicking the situation in HGPS patients. Homozygous *Lmna*^{G609G/G609G} mice appear normal at birth, but from 3 weeks of age they develop progeroid symptoms, including failure to thrive, loss of subcutaneous fat, hair follicle attrition, and bone alterations; they die at an average age of 15 weeks. These mice also exhibit hypoglycemia and altered plasma concentrations of metabolic hormones (increased growth hormone and adiponectin and reduced insulin-like growth factor 1, insulin, and leptin). *Lmna*^{G609G/G609G} mice exhibit VSMC loss in the aortic arch but not in the thoracic aorta. Longitudinal studies revealed normal blood pressure, but *Lmna*^{G609G/G609G} mice progressively developed QRS wave prolongation—consistent with altered ventricular depolarization—and bradycardia. On the other hand, heterozygous *Lmna*^{G609G/+} mice appear normal until ~32 weeks of age, when they rapidly develop a severe phenotype similar to that of homozygotes, and die shortly thereafter (92). *Lmna*^{G609G/+} mice show extensive calcification of the aortic media (93), an important feature of human HGPS. Although the *Lmna*^{G609G/G609G} mouse model recapitulates most clinical features of HGPS, there have been no reports of atherosclerosis in this model.

Lee et al. (94) recently generated a new *Lmna*^{G609G/G609G} model, which carries a HGPS-causing mutation in codon 609 of *Lmna* and produces progerin via abnormal splicing. The phenotype is similar to other HGPS mouse models, including severe VSMC loss in the media of the ascending aorta and adventitial fibrosis by 4 months of age. However, the effect of the mutation on longevity has not been reported.

4.4. *Zmpste24*^{-/-}

The final step in prelamin A maturation is the cleavage of the farnesylated C-terminus by the zinc metalloproteinase ZMPSTE24 (**Figure 1a**). Homozygous and compound heterozygous *ZMPSTE24* inactivating mutations in humans result in farnesylated prelamin A accumulation, causing various progeria-like syndromes, such as restrictive dermopathy (95–97) and mandibuloacral dysplasia (98). *Zmpste24*-deficient mice expressing farnesylated prelamin A thus present an appropriate preclinical model for studying premature aging. *Zmpste24*^{-/-} mice generated by Bergo et al. (99) show postnatal growth retardation, alopecia, reduced subcutaneous fat, muscle weakness, and bone abnormalities and die by 6–7 months of age. The *Zmpste24*^{-/-} mouse model generated by Pendás et al. (100) has a slightly more severe phenotype, including postnatal growth retardation, alopecia, lipodystrophy, skeletal and muscular atrophy, cardiac alterations (dilation of both ventricles, interstitial fibrosis, and ventricular wall thinning), and death at an average age of 5 months. Recent studies in this progeroid model revealed electrical cardiac alterations associated with connexin 43 mislocalization (see below) (76).

5. HUTCHINSON-GILFORD PROGERIA SYNDROME: GENERAL MECHANISMS AND TREATMENTS

Lamin A/C play major roles in a broad range of cell functions, including maintenance of nuclear mechanical stability, signal transduction, gene transcription, chromatin organization, DNA damage repair, cell-cycle progression, and cell differentiation and migration (71). By affecting multiple pathways, progerin and prelamin A accumulation may therefore trigger premature aging through a number of nonmutually exclusive mechanisms. Moreover, the profile of activated mechanisms might differ between different tissues depending on differences in the amount of lamin A (and therefore progerin) produced, which is related to tissue stiffness (101).

Mouse and human studies suggest that HGPS severity is determined by both the total amount of progerin and the ratio of farnesylated progerin to mature lamin A. Indeed, different human *LMNA* point mutations are associated with major differences in progerin levels and disease severity, ranging from neonatal progeria (high progerin level) to late-onset progeria (low progerin level) (102–104). Accordingly, in *Lmna*^{G609G/G609G} mice, the aging phenotype is ameliorated, and survival is prolonged by the reduction in progerin expression with antisense morpholinos targeting aberrant *Lmna* exon 11–exon 12 splicing (92). Progerin production, adventitial fibrosis, and VSMC loss in *Lmna*^{G609G/G609G} mice are also reduced by antisense oligonucleotides designed to shift alternative splicing from lamin A toward lamin C; however, the effect of this strategy on longevity was not reported (94).

Unlike mature lamin A, progerin remains permanently farnesylated (**Figure 1**). The hypothesis that persistent farnesylation is a chief cause of progeria was supported by mouse and human studies demonstrating progeroid symptoms associated with farnesylated prelamin A accumulation caused by *ZMPSTE24* deficiency (95–100). Moreover, a patient with both a homozygous loss-of-function *ZMPSTE24* mutation and a heterozygous *LMNA* mutation resulting in C-terminal elongation of the final lamin A had a milder-than-usual progeroid phenotype, possibly due to reduced levels of farnesylated prelamin A (105). Supporting this conclusion, *Zmpste24*^{-/-} mice with *Lmna* haploinsufficiency display no overt aging phenotype (106). The importance of farnesylation in HGPS pathogenesis was confirmed by the generation of *Lmna*^{csmlHG/csmHG} mice, which produce nonfarnesylated progerin and do not age prematurely (107). Likewise, *Lmna*^{nPLAO/nPLAO} mice, expressing only nonfarnesylated prelamin A, develop cardiomyopathy but not progeria (108). Moreover, treatment with farnesyl transferase inhibitors (FTIs) diminishes nuclear defects in progerin-expressing cells (88, 109), prevents CVD onset and late progression in progeroid *G608G BAC* mice (110), and prolongs the survival of progeroid *Zmpste24*^{-/-} and *Lmna*^{HG/+} mice (89, 111).

Later work showed that FTI treatment results in alternative geranylgeranyltransferase-mediated prenylation of prelamin A and progerin (112), similar to the effect of FTIs on some oncoproteins in cancer therapy (113). Combined treatment of *Zmpste24*^{-/-} mice with statins and aminobisphosphonates to block both prelamin A farnesylation and geranylgeranylation improved the progeroid phenotype and prolonged life span (112). On the basis of findings in progerin- and prelamin A–expressing mice and cells (reviewed in 10), clinical trials have been conducted on HGPS patients to test the effect of treatment with an FTI (lonafarnib) alone or in combination with statins (pravastatin) and bisphosphonates (zoledronate) (72, 78, 87). Lonafarnib monotherapy provided some improvement in vascular stiffness, bone structure, and audiological status and was estimated to increase mean survival by 1.6 years (72, 87). Triple-drug therapy with lonafarnib, pravastatin, and zoledronate showed an additional improvement in bone mineral density, but there was no cardiovascular improvement compared with lonafarnib monotherapy (78). Thus, although farnesylated progerin appears to play a major role in HGPS, current therapies to prevent progerin farnesylation appear to provide only a modest benefit.

FTI: farnesyl transferase inhibitor

mTOR: mammalian target of rapamycin

The observation that unfarnesylated and farnesylated progerin both accumulate at the nuclear membrane prompted Kalinowski et al. (114) to suggest that progerin association with the inner nuclear membrane also involves increased electrostatic interactions and aggregation. In addition, the less heterogeneous and more compact tail of progerin compared with normal lamin A may affect its interaction with DNA and other proteins (115).

Another factor that might contribute to progerin toxicity is altered protein structure, due to the deletion of 50 amino acids near the C-terminal region. Abnormal interactions of progerin with other nuclear components cause nuclear blebbing, increased thickness and stiffness of the nuclear lamina, heterochromatin mislocalization, and alterations to nuclear pore complexes (116, 117). Recently, Lee et al. (118) found that progerin binds strongly to lamin A/C and that chemical disruption of progerin-lamin A/C heterodimers reduces nuclear aberrations, prevents cell senescence, ameliorates progeroid features, and extends the life span of *Lmna*^{G609G/G609G} mice.

ICMT-catalyzed carboxymethylation of the progerin C-terminal farnesylcysteine residue might also play a role in progeria. Reducing ICMT expression and activity by 70–90% in hypomorphic *Zmpste24*^{-/-}*Icmt*^{bm/bm} mice improved body weight, grip strength, and bone structure and extended survival compared with control *Zmpste24*^{-/-}*Icmt*^{+/+} littermates with intact ICMT (119). Diminished ICMT activity in *Zmpste24*^{-/-}*Icmt*^{bm/bm} mice was associated with prelamin A mislocalization and activation of signaling through AKT (protein kinase B) and mTOR (mammalian target of rapamycin), in turn delaying cell senescence. However, it is noteworthy that the mTOR inhibitor rapamycin activated autophagic clearance of progerin and reduced nuclear abnormalities (120, 121). These results clearly show that ICMT and mTOR are implicated in premature aging, but further studies are needed to define the precise underlying mechanisms and relationship between ICMT, AKT, and mTOR.

6. MECHANISMS UNDERLYING CARDIOVASCULAR DISEASE IN PROGERIA

This section summarizes current knowledge of the cellular and molecular mechanisms through which prelamin A and progerin damage the cardiovascular system. This knowledge is of major interest for understanding the mechanisms implicated in CVD during normal aging, because both prelamin A and progerin are expressed at low levels in cells and tissues of non-HGPS individuals, including medial VSMCs and atherosclerotic lesions (14, 15, 122).

6.1. Vascular Smooth Muscle Cell Loss

Progressive VSMC loss is a characteristic of HGPS patients (14, 79, 91) and progeria mouse models (90, 92, 94), suggesting an important role in progeroid vascular disease. Although less severe, depletion of VSMCs in the media also occurs in physiological aging (123).

VSMCs are subject to high mechanical stress related to blood flow. In normal conditions, cells respond to shear stress by increasing the expression of lamin A/C and changing their nuclear localization (101, 124, 125). Abnormal responses to physical stress in progerin-expressing cells may lead to cell damage and death (117, 126). Consistent with this notion, sustained mechanical stress applied to HGPS fibroblasts reduces cell viability and increases apoptotic cell death (127). Progerin-induced alterations in mechanotransduction might be explained by changes in the expression of proteins controlling cytoskeleton organization, mechanotransduction, and ECM production (128, 129). Supporting this view, the ascending aorta of progerin-expressing *G608G BAC* transgenic mice have reduced expression of vimentin (128), a cytoskeletal protein attached to the nucleus, endoplasmic reticulum, and mitochondria that is essential for maintaining cellular

integrity (130). This correlation between mechanotransduction protein downregulation and high shear stress might partially explain VSMC loss in HGPS.

The mechanisms underlying progerin-induced VSMC loss can be explored in human smooth muscle cells (SMCs) differentiated from induced pluripotent stem cells (iPSCs) derived from healthy individuals and HGPS patients. Liu et al. (131) reported premature senescence associated with vascular aging in iPSC-derived progerin-expressing SMCs and identified the interaction between progerin and the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a catalytic subunit of nuclear DNA-PK that participates in DNA repair by nonhomologous end joining (NHEJ). Conflicting with these findings, Kinoshita et al. (132) reported that progerin, unlike wild-type lamin A, cannot interact with DNA-PK or other proteins implicated in the DNA damage response. They also found that expression of progerin in VSMCs, but not in ECs, causes DNA-PK activation, leading to VSMC growth arrest and senescence. Further studies are thus warranted to clarify the interaction between progerin and DNA-PK and its subunits in different cell types and to map out its pathophysiological consequences.

Zhang et al. (133) reported caspase-independent severe proliferative defects in SMCs derived from HGPS-iPSCs. They also found that progerin expression in SMCs inhibits poly(ADP-ribose) polymerase 1, an important DNA repair regulator, and activates the error-prone NHEJ response, causing prolonged mitosis, mitotic catastrophe, and cell death. Prelamin A also induces DNA damage and increases the DNA damage response in aged VSMCs (15, 134). This response might be a consequence of impaired recruitment of 53 binding protein 1 to DNA damage sites, resulting from defective nuclear import related to nucleoporin 153 mislocalization (135). Defective DNA damage repair has also been described in nonvascular HGPS cells and progeria mouse models (136–138). These accumulated findings confirm that a defective DNA damage response contributes to progerin-driven VSMC death. Remarkably, DNA damage plays an important role in normal aging (139).

6.2. Vascular Calcification

Similar to HGPS patients (14, 81–83), progeroid *G608G BAC* and *Lmna*^{G609G/+} mice develop aortic calcification (90, 93). In the calcified aortas of *Lmna*^{G609G/+} mice, Villa-Bellosta et al. (93) found abnormally high expression of the osteogenic markers bone morphogenetic protein 2 (Bmp2) and Run-related transcription factor 2 (Runx2), without alterations in the anticalcification agents, matrix Gla-protein and fetuin A. Moreover, *Lmna*^{G609G/+}-derived primary VSMCs showed a reduced capacity to inhibit calcium deposition in vitro, which was associated with lower concentration of extracellular inorganic pyrophosphate (ePPi), the major endogenous inhibitor of VC. Reduced ePPi levels in VSMC cultures were associated with impaired ePPi synthesis due to decreased adenosine 5'-triphosphate (ATP) production (the main substrate for ePPi synthesis) and upregulation of both tissue-nonspecific alkaline phosphatase (TNAP, the main enzyme causing PPi hydrolysis) and ectonucleoside triphosphatase diphosphohydrolase 1 (eNTPD1, an enzyme that hydrolyzes ATP to release inorganic phosphate). Compared with *Lmna*^{+/+} littermates, *Lmna*^{G609G/+} mice had lower plasma concentrations of ePPi and ATP, and treatment with exogenous PPi prevented VC in *Lmna*^{G609G/G609G} mice (93).

Prelamin A expression in VSMCs also promotes VC through a mechanism involving the activation of signaling via the DNA damage-related ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-related pathway (134). Activation of this pathway induces the senescence-associated secretory phenotype in VSMCs, which release procalcification factors such as BMP2 that can trigger calcification both locally and at remote sites (134). Moreover, exposure of VSMC cultures to a calcifying medium leads to upregulation of lamin A and prelamin A expression,

SMC: smooth muscle cell

iPSC: induced pluripotent stem cell

DNA-PKcs: DNA-dependent protein kinase catalytic subunit

NHEJ: nonhomologous end joining

Bmp2/BMP2: bone morphogenetic protein 2

Runx2: Run-related transcription factor 2

ePPi: extracellular inorganic pyrophosphate

ATP: adenosine 5'-triphosphate

accompanied by augmented expression of procalcification factors such as Runx2, osteocalcin, osteopontin, and increased calcium deposition (140). Remarkably, human mesenchymal stem cells expressing progerin also have elevated levels of osteopontin and show enhanced osteogenic differentiation (141).

In summary, lamin A and its mutant or unprocessed forms participate in osteoblastic VSMC differentiation and VC, underlying the need to deepen our knowledge about the role of progerin and prelamin A in VC during normal and premature aging.

6.3. Endothelial Dysfunction

EC dysfunction plays a key role in all stages of atherosclerosis, which is the life-threatening symptom of HGPS. ECs sense and respond to different types of blood flow, and aortic regions subjected to turbulent blood flow and high shear stress, such as the ascending aorta, are more susceptible to atherosclerosis (142, 143). Song et al. (128) observed intact EC monolayers in regions of the ascending aorta of *G608G BAC* mice that were almost completely devoid of VSMCs. Compared with ECs in regions with preserved VSMCs, progerin-expressing ECs near regions with massive VSMC loss have more than eightfold higher vimentin expression, which might make them more resistant to shear stress, thus explaining the presence of well-preserved endothelium in HGPS vessels (14).

Elevated adhesion molecule expression in dysfunctional ECs triggers monocyte adhesion, an important step in atherosclerosis initiation and progression (62). Recent studies show that prelamin A accumulation in ECs, accomplished by blocking lamin A maturation, induces cell senescence and promotes intercellular adhesion molecule 1-dependent monocyte adhesion (144). Further studies are needed to determine the connection between ECs, progerin, and prelamin A expression and atheroma build-up.

6.4. Cardiac Electrical Alterations

Consistent with the HGPS patients who have repolarization abnormalities, progeroid *Zmpste24*^{-/-} mice progressively develop T-wave flattening (75, 76). Moreover, both progerin-expressing *Lmna*^{G609G/G609G} mice and prelamin A-expressing *Zmpste24*^{-/-} mice develop severe bradycardia with aging (76, 92). Aging is also associated with QRS prolongation in *Lmna*^{G609G/G609G} mice and with PQ and QRS prolongation in *Zmpste24*^{-/-} mice, indicating defective cardiac conduction. These alterations may reflect intercellular connectivity defects, because the gap junction protein connexin 43 is mislocalized in myocardial tissue of HGPS patients and *Zmpste24*^{-/-} mice. These results suggest that cardiac alterations in HGPS patients and progeroid mice are a characteristic of progeria that could increase the risk of arrhythmias and lead to premature death. Moreover, some of the alterations in the progeroid heart are also frequently observed during normal aging (145, 146), suggesting the existence of common mechanisms underlying heart alterations in HGPS patients and in the geriatric population.

7. CONCLUDING REMARKS AND PERSPECTIVES

Aging is the predominant risk factor for CVD. Because societies are progressively aging, and CVD is the main cause of morbimortality worldwide, we urgently need to improve our knowledge of the mechanisms underlying tissue and organismal aging. This information is critical to the development of new strategies to reduce disease burden in the elderly and thus promote healthy aging. Intense efforts in basic, clinical, and epidemiological research have identified general mechanisms

implicated in aging. These were recently classified into primary hallmarks of aging (genomic instability, telomere attrition, epigenetic alterations, and loss of proteostasis) that trigger antagonistic hallmarks (deregulated nutrient sensing, mitochondrial dysfunction, and cellular senescence), leading to integrative hallmarks (stem cell exhaustion and altered intercellular communication) (6). A challenge in aging research is to identify which of the aging hallmarks contribute most in explaining the high interindividual variability in human biological aging, as well as to understand their relative contribution to age-associated cardiovascular damage. This knowledge should help researchers to develop new therapies and improve prevention by identifying individuals at higher risk of suffering age-related diseases before symptoms appear, thus promoting healthy aging and reducing the health care and socioeconomic impacts of aging.

Aging and CVD are strongly accelerated in patients with HGPS, a rare genetic disorder caused by the unprocessed form of lamin A called progerin. Human progeria is also linked to abnormal accumulation of prelamin A caused by inactivating mutations in *ZMPSTE24*. Remarkably, both prelamin A and progerin are expressed at low levels in cells and tissues from normally aging individuals, including cells of the artery wall. Progeria research can therefore shed light on the cell and molecular mechanisms driving normal aging and associated CVD. Traditional cardiovascular risk factors such as hypercholesterolemia, diabetes, obesity, hypertension, and smoking are typically absent or only mildly expressed in HGPS patients; therefore, research into this disease offers a unique opportunity to isolate mechanisms that directly cause age-dependent cardiovascular damage from modifiable risk factors that progressively deteriorate cells and tissues during aging and can secondarily influence cardiovascular health.

The identification of specific and shared mechanisms involved in normal and premature aging will require high-throughput genomic, epigenomic, transcriptomic, proteomic, and metabolomic studies. Moreover, loss-of-function and gain-of-function studies targeting candidate factors identified in “omic” studies will permit the establishment of causal relationships. Bearing in mind the large number of cell types that participate in CVD and normal and premature aging, it will be of great interest to generate new conditional and/or tissue-specific mouse models, with special emphasis on cells known to play a major role in atherosclerosis (e.g., monocytes/macrophages, lymphocytes, ECs, and VSMCs). There is a specific need to create small and large animal models of progeria that develop atherosclerosis, one of the main causes of death in HGPS patients. In cells from non-HGPS individuals, oxidative stress and telomere shortening have been proposed to induce prelamin A and progerin expression, respectively (15, 16). Further research should focus on understanding how physiological aging leads to the accumulation of unprocessed forms of lamin A and whether nuclear abnormalities induced by these proteins contribute to normal aging.

DISCLOSURE STATEMENT

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

ACKNOWLEDGMENTS

We apologize to many colleagues whose work we could not cite due to space constraints. We thank M.J. Andrés-Manzano for help with preparation of artwork and Simon Bartlett for English editing. Work in the V.A. laboratory is supported by the Spanish Ministerio de Economía, Industria y Competitividad (MEIC) (award SAF2016–79490-R), and the Instituto de Salud Carlos III (ISCIII) (awards RD12/0042/0028 and AC16/00091), with cofunding from the Fondo Europeo de Desarrollo Regional (FEDER), the Fundació Marató TV3 (grant 122/C/2015), and the

Progeria Research Foundation (Established Investigator Award 2014-52). L.d.C. is the recipient of a Jordi Soler postdoctoral fellowship from the Red de Investigación Cardiovascular at ISCIII. The CNIC is supported by the MEIC and the Pro-CNIC Foundation and is a Severo Ochoa Center of Excellence (MEIC award SEV-2015-0505).

LITERATURE CITED

1. D'Agostino RB Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, et al. 2008. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation* 117:743–53
2. Savji N, Rockman CB, Skolnick AH, Guo Y, Adelman MA, et al. 2013. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. *J. Am. Coll. Cardiol.* 61:1736–43
3. United Nations (UN). 2002. *World population ageing, 1950–2050*. Rep., Dep. Econ. Social Aff., Pop. Div., UN, New York. <http://www.un.org/esa/population/publications/worldageing19502050/>
4. Future Health. 2016. *The future of health care: deep data, smart sensors, virtual patients, and the Internet-of-Humans*. Manifesto 2016. Future Health, Berlin. https://docs.wixstatic.com/ugd/2b9f87_40d29af47a9742498cbbbd484e0174e0.pdf
5. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, et al. 2011. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. *Circulation* 123:933–44
6. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. 2013. The hallmarks of aging. *Cell* 153:1194–217
7. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, et al. 2003. Recurrent *de novo* point mutations in lamin A cause Hutchinson–Gilford progeria syndrome. *Nature* 423:293–98
8. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, et al. 2003. Lamin A truncation in Hutchinson–Gilford progeria. *Science* 300:2055
9. Barrowman J, Wiley PA, Hudon-Miller SE, Hrycyna CA, Michaelis S. 2012. Human ZMPSTE24 disease mutations: residual proteolytic activity correlates with disease severity. *Hum. Mol. Genet.* 21:4084–93
10. Gordon LB, Rothman FG, López-Otín C, Misteli T. 2014. Progeria: a paradigm for translational medicine. *Cell* 156:400–7
11. Dorado B, Andrés V. 2017. A-type lamins and cardiovascular disease in premature aging syndromes. *Curr. Opin. Cell Biol.* 46:17–25
12. Reddy S, Comai L. 2012. Lamin A, farnesylation and aging. *Exp. Cell Res.* 318:1–7
13. Capell BC, Tloulgan BE, Orlow SJ. 2009. From the rarest to the most common: insights from progeroid syndromes into skin cancer and aging. *J. Invest. Dermatol.* 129:2340–50
14. Olive M, Harten I, Mitchell R, Beers JK, Djabali K, et al. 2010. Cardiovascular pathology in Hutchinson–Gilford progeria: correlation with the vascular pathology of aging. *Arterioscler. Thromb. Vasc. Biol.* 30:2301–9
15. Ragnauth CD, Warren DT, Liu Y, McNair R, Tajsic T, et al. 2010. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. *Circulation* 121:2200–10
16. Cao K, Blair CD, Faddah DA, Kieckhafer JE, Olive M, et al. 2011. Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts. *J. Clin. Invest.* 121:2833–44
17. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., et al. 2013. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J. Am. Coll. Cardiol.* 62:e147–239
18. Ho KK, Pinsky JL, Kannel WB, Levy D. 1993. The epidemiology of heart failure: the Framingham Study. *J. Am. Coll. Cardiol.* 22:6a–13a
19. Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, et al. 2001. Importance of heart failure with preserved systolic function in patients ≥ 65 years of age. *Am. J. Cardiol.* 87:413–19
20. Wong J, Chabiniok R, deVecchi A, Dedieu N, Sammut E, et al. 2016. Age-related changes in intraventricular kinetic energy: a physiological or pathological adaptation? *Am. J. Physiol. Heart Circ. Physiol.* 310:H747–55

21. Lakatta EG, Levy D. 2003. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part II: the aging heart in health: links to heart disease. *Circulation* 107:346–54
22. Martos R, Baugh J, Ledwidge M, O’Loughlin C, Conlon C, et al. 2007. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. *Circulation* 115:888–95
23. Benjamin EJ, Levy D, Anderson KM, Wolf PA, Plehn JF, et al. 1992. Determinants of Doppler indexes of left ventricular diastolic function in normal subjects (the Framingham Heart Study). *Am. J. Cardiol.* 70:508–15
24. Carrick-Ranson G, Hastings JL, Bhella PS, Shibata S, Fujimoto N, et al. 2012. Effect of healthy aging on left ventricular relaxation and diastolic suction. *Am. J. Physiol. Heart Circ. Physiol.* 303:H315–22
25. Swinne CJ, Shapiro EP, Lima SD, Fleg JL. 1992. Age-associated changes in left ventricular diastolic performance during isometric exercise in normal subjects. *Am. J. Cardiol.* 69:823–26
26. Lester SJ, Tajik AJ, Nishimura RA, Oh JK, Khandheria BK, Seward JB. 2008. Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. *J. Am. Coll. Cardiol.* 51:679–89
27. Dai DF, Chen T, Johnson SC, Szeto H, Rabinovitch PS. 2012. Cardiac aging: from molecular mechanisms to significance in human health and disease. *Antioxid. Redox Signal.* 16:1492–526
28. Eng J, McClelland RL, Gomes AS, Hundley WG, Cheng S, et al. 2016. Adverse left ventricular remodeling and age assessed with cardiac MR imaging: the multi-ethnic study of atherosclerosis. *Radiology* 278:714–22
29. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. 1988. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. *Ann. Intern. Med.* 108:7–13
30. Gerstenblith G, Frederiksen J, Yin FC, Fortuin NJ, Lakatta EG, Weisfeldt ML. 1977. Echocardiographic assessment of a normal adult aging population. *Circulation* 56:273–78
31. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. 1989. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham Heart Study. *Ann. Intern. Med.* 110:101–7
32. Olivetti G, Giordano G, Corradi D, Melissari M, Lagrasta C, et al. 1995. Gender differences and aging: effects on the human heart. *J. Am. Coll. Cardiol.* 26:1068–79
33. Lima JA. 2017. The aging human heart. *Circ. Cardiovasc. Imaging* 10:e005899
34. Biernacka A, Frangogiannis NG. 2011. Aging and cardiac fibrosis. *Aging Dis.* 2:158–73
35. Segura AM, Frazier OH, Buja LM. 2014. Fibrosis and heart failure. *Heart Fail. Rev.* 19:173–85
36. Horn MA. 2015. Cardiac physiology of aging: extracellular considerations. *Compr. Physiol.* 5:1069–121
37. Piek A, de Boer RA, Sillje HH. 2016. The fibrosis-cell death axis in heart failure. *Heart Fail. Rev.* 21:199–211
38. Spadaccio C, Mozetic P, Nappi F, Nenna A, Sutherland F, et al. 2016. Cells and extracellular matrix interplay in cardiac valve disease: because age matters. *Basic Res. Cardiol.* 111:16
39. Fleg JL, O’Connor F, Gerstenblith G, Becker LC, Clulow J, et al. 1995. Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. *J. Appl. Physiol.* 78:890–900
40. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. 2014. Epidemiology of atrial fibrillation: European perspective. *Clin. Epidemiol.* 6:213–20
41. Levy S. 2002. Atrial fibrillation, the arrhythmia of the elderly, causes and associated conditions. *Anadolu Kardiyol. Derg.* 2:55–60
42. Nguyen TN, Hilmer SN, Cumming RG. 2013. Review of epidemiology and management of atrial fibrillation in developing countries. *Int. J. Cardiol.* 167:2412–20
43. Moghtadai M, Jansen HJ, Mackasey M, Rafferty SA, Bogachev O, et al. 2016. The impacts of age and frailty on heart rate and sinoatrial node function. *J. Physiol.* 594:7105–26
44. Taylor JA, Tan CO. 2014. BP regulation VI: elevated sympathetic outflow with human aging: hypertensive or homeostatic? *Eur. J. Appl. Physiol.* 114:511–19
45. Ferrari AU, Radaelli A, Centola M. 2003. Invited review: aging and the cardiovascular system. *J. Appl. Physiol.* 95:2591–97
46. Schulman SP, Lakatta EG, Fleg JL, Lakatta L, Becker LC, Gerstenblith G. 1992. Age-related decline in left ventricular filling at rest and exercise. *Am. J. Physiol.* 263:H1932–38
47. Lakatta EG, Levy D. 2003. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a “set up” for vascular disease. *Circulation* 107:139–46

48. Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, et al. 1997. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. *Circulation* 96:308–15
49. Sun Z. 2015. Aging, arterial stiffness, and hypertension. *Hypertension* 65:252–56
50. Veerman DP, Imholz BP, Wieling W, Karemaker JM, van Montfrans GA. 1994. Effects of aging on blood pressure variability in resting conditions. *Hypertension* 24:120–30
51. Monahan KD. 2007. Effect of aging on baroreflex function in humans. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 293:R3–12
52. Paneni F, Diaz Cañestro C, Libby P, Lüscher TF, Camici GG. 2017. The aging cardiovascular system: understanding it at the cellular and clinical levels. *J. Am. Coll. Cardiol.* 69:1952–67
53. Vlachopoulos C, Aznaouridis K, Stefanadis C. 2010. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J. Am. Coll. Cardiol.* 55:1318–27
54. Mitchell GF, Guo CY, Benjamin EJ, Larson MG, Keyes MJ, et al. 2007. Cross-sectional correlates of increased aortic stiffness in the community: the Framingham Heart Study. *Circulation* 115:2628–36
55. Mitchell GF, Hwang SJ, Vasani RS, Larson MG, Pencina MJ, et al. 2010. Arterial stiffness and cardiovascular events: the Framingham Heart Study. *Circulation* 121:505–11
56. Wang M, Monticone RE, Lakatta EG. 2014. Proinflammation of aging central arteries: a mini-review. *Gerontology* 60:519–29
57. Kohn JC, Lampi MC, Reinhart-King CA. 2015. Age-related vascular stiffening: causes and consequences. *Front. Genet.* 6:112
58. Huvencers S, Daemen MJ, Hordijk PL. 2015. Between Rho(k) and a hard place: the relation between vessel wall stiffness, endothelial contractility, and cardiovascular disease. *Circ. Res.* 116:895–908
59. Alenghat FJ. 2016. The prevalence of atherosclerosis in those with inflammatory connective tissue disease by race, age, and traditional risk factors. *Sci. Rep.* 6:20303
60. Bae JH, Kim WS, Lee MS, Kim KS, Park JB, et al. 2016. The changes of individual carotid artery wall layer by aging and carotid intima-media thickness value for high risk. *Cardiovasc. Ther.* 34:397–403
61. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. 1999. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. *N. Engl. J. Med.* 340:14–22
62. Libby P, Hansson GK. 2015. Inflammation and immunity in diseases of the arterial tree: players and layers. *Circ. Res.* 116:307–11
63. Sanz-González SM, Poch E, Pérez-Roger I, Díez-Juan A, Ivorra C, Andrés V. 2000. Control of vascular smooth muscle cell growth by cyclin-dependent kinase inhibitory proteins and its implication in cardiovascular disease. *Front. Biosci.* 5:D619–28
64. Fisher SA. 2010. Vascular smooth muscle phenotypic diversity and function. *Physiol. Genom.* 42a:169–87
65. Kaplan H, Thompson RC, Trumble BC, Wann LS, Allam AH, et al. 2017. Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study. *Lancet* 389:1730–39
66. Wissler RW, Strong JP, PDAY Res. Group. 1998. Risk factors and progression of atherosclerosis in youth. *Am. J. Pathol.* 153:1023–33
67. Allam AH, Thompson RC, Wann LS, Miyamoto MI, Nur el-Din AH, et al. 2011. Atherosclerosis in ancient Egyptian mummies: the Horus study. *JACC Cardiovasc. Imaging* 4:315–27
68. Lin F, Worman HJ. 1993. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. *J. Biol. Chem.* 268:16321–26
69. Furukawa K, Inagaki H, Hotta Y. 1994. Identification and cloning of an mRNA coding for a germ cell-specific A-type lamin in mice. *Exp. Cell Res.* 212:426–30
70. Machiels BM, Zorenc AH, Endert JM, Kuijpers HJ, van Eys GJ, et al. 1996. An alternative splicing product of the lamin A/C gene lacks exon 10. *J. Biol. Chem.* 271:9249–53
71. Andrés V, González JM. 2009. Role of A-type lamins in signaling, transcription, and chromatin organization. *J. Cell Biol.* 187:945–57
72. Gordon LB, Massaro J, D'Agostino RB Sr., Campbell SE, Brazier J, et al. 2014. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. *Circulation* 130:27–34
73. Ullrich NJ, Gordon LB. 2015. Hutchinson-Gilford progeria syndrome. *Handb. Clin. Neurol.* 132:249–64

74. Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Kleinman ME, et al. 2012. Mechanisms of premature vascular aging in children with Hutchinson–Gilford progeria syndrome. *Hypertension* 59:92–97
75. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, et al. 2008. Phenotype and course of Hutchinson–Gilford progeria syndrome. *N. Engl. J. Med.* 358:592–604
76. Rivera-Torres J, Calvo CJ, Llach A, Guzmán-Martínez G, Caballero R, et al. 2016. Cardiac electrical defects in progeroid mice and Hutchinson–Gilford progeria syndrome patients with nuclear lamina alterations. *PNAS* 113:E7250–59
77. Gordon LB, Harten IA, Patti ME, Lichtenstein AH. 2005. Reduced adiponectin and HDL cholesterol without elevated C-reactive protein: clues to the biology of premature atherosclerosis in Hutchinson–Gilford Progeria Syndrome. *J. Pediatr.* 146:336–41
78. Gordon LB, Kleinman ME, Massaro J, D’Agostino RB Sr., Shappell H, et al. 2016. Clinical trial of the protein farnesylation inhibitors lonafarnib, pravastatin, and zoledronic acid in children with Hutchinson–Gilford progeria syndrome. *Circulation* 134:114–25
79. Stehbins WE, Delahunt B, Shozawa T, Gilbert-Barness E. 2001. Smooth muscle cell depletion and collagen types in progeric arteries. *Cardiovasc. Pathol.* 10:133–36
80. Kovacic JC, Moreno P, Nabel EG, Hachinski V, Fuster V. 2011. Cellular senescence, vascular disease, and aging: part 2 of a 2-part review: clinical vascular disease in the elderly. *Circulation* 123:1900–10
81. Hanumanthappa NB, Madhusudan G, Mahimarangaiah J, Manjunath CN. 2011. Hutchinson–Gilford progeria syndrome with severe calcific aortic valve stenosis. *Ann. Pediatr. Cardiol.* 4:204–6
82. Nair K, Ramachandran P, Krishnamoorthy KM, Dora S, Achuthan TJ. 2004. Hutchinson–Gilford progeria syndrome with severe calcific aortic valve stenosis and calcific mitral valve. *J. Heart Valve Dis.* 13:866–69
83. Salamat M, Dhar PK, Neagu DL, Lyon JB. 2010. Aortic calcification in a patient with Hutchinson–Gilford progeria syndrome. *Pediatr. Cardiol.* 31:925–26
84. Ha JW, Shim WH, Chung NS. 1993. Cardiovascular findings of Hutchinson–Gilford syndrome: a Doppler and two-dimensional echocardiographic study. *Yonsei Med. J.* 34:352–55
85. Silvera VM, Gordon LB, Orbach DB, Campbell SE, Machan JT, Ullrich NJ. 2013. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson–Gilford progeria syndrome. *Am. J. Neuroradiol.* 34:1091–97
86. Hennekam RC. 2006. Hutchinson–Gilford progeria syndrome: review of the phenotype. *Am. J. Med. Genet. A* 140:2603–24
87. Gordon LB, Kleinman ME, Miller DT, Neuberger DS, Giobbie-Hurder A, et al. 2012. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome. *PNAS* 109:16666–71
88. Yang SH, Bergo MO, Toth JI, Qiao X, Hu Y, et al. 2005. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson–Gilford progeria syndrome mutation. *PNAS* 102:10291–96
89. Yang SH, Meta M, Qiao X, Frost D, Bauch J, et al. 2006. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson–Gilford progeria syndrome mutation. *J. Clin. Investig.* 116:2115–21
90. Varga R, Eriksson M, Erdos MR, Olive M, Harten I, et al. 2006. Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson–Gilford progeria syndrome. *PNAS* 103:3250–55
91. Stehbins WE, Wakefield SJ, Gilbert-Barness E, Olson RE, Ackerman J. 1999. Histological and ultrastructural features of atherosclerosis in progeria. *Cardiovasc. Pathol.* 8:29–39
92. Osorio FG, Navarro CL, Cadiñanos J, López-Mejía IC, Quiros PM, et al. 2011. Splicing-directed therapy in a new mouse model of human accelerated aging. *Sci. Transl. Med.* 3:106ra07
93. Villa-Bellosta R, Rivera-Torres J, Osorio FG, Acín-Pérez R, Enriquez JA, et al. 2013. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson–Gilford progeria syndrome that is ameliorated on pyrophosphate treatment. *Circulation* 127:2442–51
94. Lee JM, Nobumori C, Tu Y, Choi C, Yang SH, et al. 2016. Modulation of *LMNA* splicing as a strategy to treat prelamin A diseases. *J. Clin. Investig.* 126:1592–602

95. Navarro CL, De Sandre-Giovannoli A Bernard R, Boccaccio I, Boyer A, et al. 2004. Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. *Hum. Mol. Genet.* 13:2493–503
96. Navarro CL, Cadiñanos J, De Sandre-Giovannoli A Bernard R, Courrier S, et al. 2005. Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. *Hum. Mol. Genet.* 14:1503–13
97. Moulson CL, Go G, Gardner JM, van der Wal AC, Smitt JH, et al. 2005. Homozygous and compound heterozygous mutations in *ZMPSTE24* cause the laminopathy restrictive dermopathy. *J. Investig. Dermatol.* 125:913–19
98. Agarwal AK, Fryns JP, Auchus RJ, Garg A. 2003. Zinc metalloproteinase, *ZMPSTE24*, is mutated in mandibuloacral dysplasia. *Hum. Mol. Genet.* 12:1995–2001
99. Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, et al. 2002. *Zmpste24* deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. *PNAS* 99:13049–54
100. Pendás AM, Zhou Z, Cadiñanos J, Freije JM, Wang J, et al. 2002. Defective prelamin A processing and muscular and adipocyte alterations in *Zmpste24* metalloproteinase-deficient mice. *Nat. Genet.* 31:94–99
101. Swift J, Ivanovska IL, Buxboim A, Harada T, Dingal PC, et al. 2013. Nuclear lamin-A scales with tissue stiffness and enhances matrix-directed differentiation. *Science* 341:1240104
102. Moulson CL, Fong LG, Gardner JM, Farber EA, Go G, et al. 2007. Increased progerin expression associated with unusual *LMNA* mutations causes severe progeroid syndromes. *Hum. Mutat.* 28:882–89
103. Reunert J, Wentzell R, Walter M, Jakubiczka S, Zenker M, et al. 2012. Neonatal progeria: increased ratio of progerin to lamin A leads to progeria of the newborn. *Eur. J. Hum. Genet.* 20:933–37
104. Hisama FM, Lessel D, Leistriz D, Friedrich K, McBride KL, et al. 2011. Coronary artery disease in a Werner syndrome-like form of progeria characterized by low levels of progerin, a splice variant of lamin A. *Am. J. Med. Genet. A* 155A:3002–6
105. Denecke J, Brune T, Feldhaus T, Robenek H, Kranz C, et al. 2006. A homozygous *ZMPSTE24* null mutation in combination with a heterozygous mutation in the *LMNA* gene causes Hutchinson-Gilford progeria syndrome (HGPS): insights into the pathophysiology of HGPS. *Hum. Mutat.* 27:524–31
106. Fong LG, Ng JK, Meta M, Coté N, Yang SH, et al. 2004. Heterozygosity for *Lmna* deficiency eliminates the progeria-like phenotypes in *Zmpste24*-deficient mice. *PNAS* 101:18111–16
107. Yang SH, Chang SY, Ren S, Wang Y, Andres DA, et al. 2011. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin. *Hum. Mol. Genet.* 20:436–44
108. Davies BS, Barnes RH 2nd, Tu Y, Ren S, Andres DA, et al. 2010. An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. *Hum. Mol. Genet.* 19:2682–94
109. Toth JI, Yang SH, Qiao X, Beigneux AP, Gelb MH, et al. 2005. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. *PNAS* 102:12873–78
110. Capell BC, Olive M, Erdos MR, Cao K, Faddah DA, et al. 2008. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. *PNAS* 105:15902–7
111. Fong LG, Frost D, Meta M, Qiao X, Yang SH, et al. 2006. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. *Science* 311:1621–23
112. Varela I, Pereira S, Ugalde AP, Navarro CL, Suárez MF, et al. 2008. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. *Nat. Med.* 14:767–72
113. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, et al. 1997. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. *J. Biol. Chem.* 272:14459–64
114. Kalinowski A, Yaron PN, Qin Z, Shenoy S, Buehler MJ, et al. 2014. Interfacial binding and aggregation of lamin A tail domains associated with Hutchinson-Gilford progeria syndrome. *Biophys. Chem.* 195:43–48
115. Qin Z, Kalinowski A, Dahl KN, Buehler MJ. 2011. Structure and stability of the lamin A tail domain and HGPS mutant. *J. Struct. Biol.* 175:425–33
116. Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, et al. 2004. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. *PNAS* 101:8963–68

117. Dahl KN, Scaffidi P, Islam MF, Yodh AG, Wilson KL, Misteli T. 2006. Distinct structural and mechanical properties of the nuclear lamina in Hutchinson-Gilford progeria syndrome. *PNAS* 103:10271–76
118. Lee SJ, Jung YS, Yoon MH, Kang SM, Oh AY, et al. 2016. Interruption of progerin-lamin A/C binding ameliorates Hutchinson-Gilford progeria syndrome phenotype. *J. Clin. Investig.* 126:3879–93
119. Ibrahim MX, Sayin VI, Akula MK, Liu M, Fong LG, et al. 2013. Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria. *Science* 340:1330–33
120. Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, et al. 2011. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. *Sci. Transl. Med.* 3:89ra58
121. Graziotto JJ, Cao K, Collins FS, Krainc D. 2012. Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disorders. *Autophagy* 8:147–51
122. Leopold JA. 2013. Vascular calcification: an age-old problem of old age. *Circulation* 127:2380–82
123. Lee SJ, Park SH. 2013. Arterial ageing. *Korean Circ. J.* 43:73–79
124. Buxboim A, Swift J, Irianto J, Spinler KR, Dingal PC, et al. 2014. Matrix elasticity regulates lamin-A,C phosphorylation and turnover with feedback to actomyosin. *Curr. Biol.* 24:1909–17
125. Philip JT, Dahl KN. 2008. Nuclear mechanotransduction: response of the lamina to extracellular stress with implications in aging. *J. Biomech.* 41:3164–70
126. Booth EA, Spagnol ST, Alcoser TA, Dahl KN. 2015. Nuclear stiffening and chromatin softening with progerin expression leads to an attenuated nuclear response to force. *Soft Matter* 11:6412–18
127. Verstraeten VL, Ji JY, Cummings KS, Lee RT, Lammerding J. 2008. Increased mechanosensitivity and nuclear stiffness in Hutchinson-Gilford progeria cells: effects of farnesyltransferase inhibitors. *Aging Cell* 7:383–93
128. Song M, San H, Anderson SA, Cannon RO 3rd, Orlic D. 2014. Shear stress-induced mechanotransduction protein deregulation and vasculopathy in a mouse model of progeria. *Stem Cell Res. Ther.* 5:41
129. Brassard JA, Fekete N, Garnier A, Hoesli CA. 2016. Hutchinson-Gilford progeria syndrome as a model for vascular aging. *Biogerontology* 17:129–45
130. Katsumoto T, Mitsushima A, Kurimura T. 1990. The role of the vimentin intermediate filaments in rat 3Y1 cells elucidated by immunoelectron microscopy and computer-graphic reconstruction. *Biol. Cell* 68:139–46
131. Liu GH, Barkho BZ, Ruiz S, Diep D, Qu J, et al. 2011. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. *Nature* 472:221–25
132. Kinoshita D, Nagasawa A, Shimizu I, Ito TK, Yoshida Y, et al. 2017. Progerin impairs vascular smooth muscle cell growth via the DNA damage response pathway. *Oncotarget* 8:34045–56
133. Zhang H, Xiong ZM, Cao K. 2014. Mechanisms controlling the smooth muscle cell death in progeria via down-regulation of poly(ADP-ribose) polymerase 1. *PNAS* 111:E2261–70
134. Liu Y, Drozdov I, Shroff R, Beltran LE, Shanahan CM. 2013. Prelamin A accelerates vascular calcification via activation of the DNA damage response and senescence-associated secretory phenotype in vascular smooth muscle cells. *Circ. Res.* 112:e99–109
135. Cobb AM, Larrieu D, Warren DT, Liu Y, Srivastava S, et al. 2016. Prelamin A impairs 53BP1 nuclear entry by mislocalizing NUP153 and disrupting the Ran gradient. *Aging Cell* 15:1039–50
136. Liu B, Wang J, Chan KM, Tjia WM, Deng W, et al. 2005. Genomic instability in laminopathy-based premature aging. *Nat. Med.* 11:780–85
137. Liu B, Wang Z, Ghosh S, Zhou Z. 2013. Defective ATM-Kap-1-mediated chromatin remodeling impairs DNA repair and accelerates senescence in progeria mouse model. *Aging Cell* 12:316–18
138. Liu B, Wang Z, Zhang L, Ghosh S, Zheng H, Zhou Z. 2013. Depleting the methyltransferase Suv39h1 improves DNA repair and extends lifespan in a progeria mouse model. *Nat. Commun.* 4:1868
139. Garinis GA, van der Horst GT, Vijg J, Hoeijmakers JH. 2008. DNA damage and ageing: new-age ideas for an age-old problem. *Nat. Cell Biol.* 10:1241–47
140. Quirós-González I, Román-García P, Alonso-Montes C, Barrio-Vázquez S, Carrillo-López N, et al. 2016. Lamin A is involved in the development of vascular calcification induced by chronic kidney failure and phosphorus load. *Bone* 84:160–68

141. Scaffidi P, Misteli T. 2008. Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. *Nat. Cell Biol.* 10:452–59
142. Frangos SG, Gahtan V, Sumpio B. 1999. Localization of atherosclerosis: role of hemodynamics. *Arch. Surg.* 134:1142–49
143. Rouleau L, Rossi J, Leask RL. 2010. The response of human aortic endothelial cells in a stenotic hemodynamic environment: effect of duration, magnitude, and spatial gradients in wall shear stress. *J. Biomech. Eng.* 132:071015
144. Bonello-Palot N, Simoncini S, Robert S, Bourgeois P, Sabatier F, et al. 2014. Prelamin A accumulation in endothelial cells induces premature senescence and functional impairment. *Atherosclerosis* 237:45–52
145. Herraiz-Martínez A, Álvarez-García J, Llach A, Molina CE, Fernandes J, et al. 2015. Ageing is associated with deterioration of calcium homeostasis in isolated human right atrial myocytes. *Cardiovasc. Res.* 106:76–86
146. Jensen PN, Gronroos NN, Chen LY, Folsom AR, deFilippi C, et al. 2014. Incidence of and risk factors for sick sinus syndrome in the general population. *J. Am. Coll. Cardiol.* 64:531–38

Contents

CARDIOVASCULAR PHYSIOLOGY, *Kenneth Walsh, Section Editor*

- The Role of Autophagy in the Heart
Sebastiano Sciarretta, Yasubiro Maejima, Daniela Zablocki, and Junichi Sadoshima 1
- Aging in the Cardiovascular System: Lessons from
Hutchinson-Gilford Progeria Syndrome
Magda R. Hamczyk, Lara del Campo, and Vicente Andrés 27
- Lymphatic Dysfunction, Leukotrienes, and Lymphedema
Xinguo Jiang, Mark R. Nicolls, Wen Tian, and Stanley G. Rockson 49

CELL PHYSIOLOGY, *David Julius, Section Editor*

- Bacterial Mechanosensors
Charles D. Cox, Navid Bavi, and Boris Martinac 71

ENDOCRINOLOGY AND METABOLISM, *Holly A. Ingraham, Section Editor*

- SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx
and Efflux
Wen-Jun Shen, Salman Azhar, and Fredric B. Kraemer 95

GASTROINTESTINAL PHYSIOLOGY, *Linda Samuelson, Section Editor*

- Chemoreceptors in the Gut
S. Steensels and I. Depoortere 117

NEUROPHYSIOLOGY, *Roger Nicoll, Section Editor*

- Dynamism of an Astrocyte In Vivo: Perspectives on Identity
and Function
Kira E. Poskanzer and Anna V. Molofsky 143
- Neuromuscular Junction Formation, Aging, and Disorders
Lei Li, Wen-Cheng Xiong, and Lin Mei 159

Spinal Circuits for Touch, Pain, and Itch <i>Stephanie C. Koch, David Acton, and Martyn Goulding</i>	189
The Evolving Understanding of Dopamine Neurons in the Substantia Nigra and Ventral Tegmental Area <i>Stephanie C. Gantz, Christopher P. Ford, Hitoshi Morikawa, and John T. Williams</i>	219
Two Classes of Secreted Synaptic Organizers in the Central Nervous System <i>Michisuke Yuzaki</i>	243
RENAL AND ELECTROLYTE PHYSIOLOGY, <i>Peter Aronson, Section Editor</i>	
Epithelial Na ⁺ Channel Regulation by Extracellular and Intracellular Factors <i>Thomas R. Kleyman, Ossama B. Kashlan, and Rebecca P. Hughey</i>	263
Salt, Hypertension, and Immunity <i>A. Justin Rucker, Nathan P. Rudemiller, and Steven D. Crowley</i>	283
Mechanisms of Renal Fibrosis <i>Benjamin D. Humphreys</i>	309
SPECIAL TOPIC: MECHANOBIOLOGY, <i>Julio M. Fernández, Special Topic Editor</i>	
The Work of Titin Protein Folding as a Major Driver in Muscle Contraction <i>Edward C. Eckels, Rafael Tapia-Rojo, Jamie Andrés Rivas-Pardo, and Julio M. Fernández</i>	327
Unraveling the Mechanobiology of the Extracellular Matrix <i>Viola Vogel</i>	353
Titin Gene and Protein Functions in Passive and Active Muscle <i>Wolfgang A. Linke</i>	389
Mechanical Protein Unfolding and Degradation <i>Adrian O. Olivares, Tania A. Baker, and Robert T. Sauer</i>	413

Errata

An online log of corrections to *Annual Review of Physiology* articles may be found at <http://www.annualreviews.org/errata/physiol>